Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249119 | 1.00 | HSD11B1 (0.37) | HSD11B1AKR1C3HRH3DPP4MEN1 | |
| SCHEMBL20249134 | 0.86 | HRH3 (0.42) | HSD11B1HRH3DPP4MEN1KMT2A | |
| SCHEMBL20249135 | 0.86 | HRH3 (0.42) | HSD11B1HRH3DPP4MEN1KMT2A | |
| SCHEMBL20249330 | 0.84 | DPP4 (0.39) | AKR1C3DPP4MEN1KMT2A | |
| SCHEMBL20037834 | 0.82 | DRD3 (0.40) | AKR1C3HRH3MEN1KMT2ATSHR | |
| SCHEMBL22650730 | 0.81 | ALOX5AP (0.40) | AKR1C3HRH3PIK3CAMTOR | |
| SCHEMBL20037471 | 0.80 | HRH3 (0.39) | AKR1C3HRH3MEN1KMT2AGPR119 | |
| SCHEMBL18291570 | 0.80 | HRH3 (0.39) | AKR1C3HRH3MEN1KMT2AGPR119 | |
| SCHEMBL20255094 | 0.79 | HRH3 (0.38) | HRH3LMNA | |
| SCHEMBL20249098 | 0.77 | MAPT (0.46) | HSD11B1HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HSD11B1 1477/4885AKR1C3 2289/4885HRH3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.